Close Menu

Eric Rasmussen, Bryan Baldasare

Jun 25, 2019

Meridian Bioscience has announced that Eric Rasmussen has resigned his position as executive vice president and CFO effective June 28, 2019 in order to pursue other opportunities. Meridian has appointed Bryan Baldasare, currently its senior vice president, corporate controller, treasurer, and chief accounting officer, to serve as interim CFO.

More Like This

Jan 24, 2020

Guardant Health: Kumud Kalia

Guardant Health has appointed Kumud Kalia as its new chief information officer. In the role, he will lead the company's enterprise applications, information technology, and security teams. Kalia was most recently chief information and technology officer at Cylance, and previously served the same role at Akamai Technologies. He received Computerworld's "best in class" recognition among its 100 premier information technology leaders and has led teams that have won CIO100, CTO25, and other industry awards. He holds an honors degree in electronic engineering from Bangor University, is a chartered engineer, and is a fellow of both the Institution of Engineering and Technology and the British Computer Society.

Jan 23, 2020

Agilent Technologies: Mark Doak, Padriag McDonnell

Agilent Technologies said this week that Mark Doak will retire as senior VP of the firm and president of Agilent CrossLab Group, effective May 1, 2020. Agilent has named Padraig McDonnell, currently VP and general manager of the firm's chemistries and supplies division, to succeed Doak. McDonnell has served in various roles at Agilent for 22 years.  

Jan 21, 2020

GenMark Diagnostics: James McNally

GenMark Diagnostics said that on Jan. 9, it notified James McNally, its senior vice president of marketing and business development, that his employment with the firm would cease on Jan. 10.

In a filing with the US Securities and Exchange Commission, GenMark also said that on Jan. 14, it entered into a separation agreement and general release with McNally. In accordance with the agreement, McNally is entitled to benefits, including a gross lump sum payment equal to six months of his base salary in effect as of the separation date; an amount equal to McNally’s target bonus percentage under the firm's 2019 bonus plan multiplied by a percentage tied to the achievement of the company-level performance targets under the plan; and an aggregate of 35,702 restricted stock units held by McNally as of the separation date.

Jan 15, 2020

AACC: Janet Kreizman

American Association of Clinical Chemistry CEO Janet Kreizman is retiring from the organization in the second quarter of 2020, the organization said. She has been with AACC for almost seven years. During her tenure, AACC created a first-of-its kind point-of-care testing professional certification and the launch of its second peer-reviewed journal, AACC noted. Prior to joining AACC, she was the deputy executive director and chief policy officer at the Endocrine Society, according to her LinkedIn profile. AACC's board is organizing the search process for a new CEO. 

Jan 14, 2020

Geneoscopy: Mark Van Cleve

Geneoscopy has appointed Mark Van Cleve its vice president of product development. He has more than 25 years of experience in the design and development of in vitro diagnostic products and technologies and was most recently head of R&D, Clinical Lab Menue at Ortho Clinical Diagnostics. Before that, he was VP of R&D at Hycor Biomedical. He has also held positions at Agilent Technologies, Chiron, and BD Biosciences. 

Jan 14, 2020

Myriad Genetics: Thomas Slavin

Thomas Slavin will be senior VP of medical affairs at Myriad Genetics' oncology division. Starting March 2, he will report to Nicole Lambert, president of Myriad Oncology, and be in charge of Myriad's portfolio of molecular and companion diagnostic products and services for oncology. Slavin is board certified in clincial genetics, medical diagnostics, and pediatrics, and most recently was an assistant professor in City of Hope National Medical Center's medical oncology & therapeutics research and population sciences division. 

Jan 13, 2020

T2 Biosystems: Tony Pare

T2 Biosystems has promoted Tony Pare to the newly created position of chief commercial officer, effective immediately. Pare previously served as vice president and general manager of T2 Biosystems' international business. Prior to that, he held senior business development positions at Haemonetics and Hemanext.

Jan 13, 2020

Spartan Bioscience: Dirk Sibbing; Gilles Montalescot; Marco Valgimigli; Davide Capodanno

Spartan Bioscience has establishd a scientific advisory board in Europe. The members are Dirk Sibbing, an inverventional cardiologist and professor of cardiology at Ludwig-Miximilians University in Munich; Gilles Montalescot, a professor of cardiology at the University of Paris VI, and director of the cardiac care unit at Pitié-Salpêtrière Hospital, Paris; Marco Valgimigli, associate professor of cardiology and senior interventional cardiology at Inselspital Universitätsspital in Bern, Switzerland; and Davide Capodanno, associate professor of cardiology at the University of Catania, Italy, and interventional cardiologist, Azienda ""Policlinico-Vittorio Emanuele" in Catania. The company added that a North American team will be announced in March at the American College of Cardiology conference. 

Jan 13, 2020

Foundation Medicine: Ritesh Khullar

Ritesh (Tesh) Khullar has been appointed as chief commercial officer of Foundation Medicine, effective Jan. 20. He joins the Roche subsidiary from Flatiron Health, where he was responsible for leading and scaling provider service offerings. Prior to that, he was the national VP and general manager of sales and account management at McKesson Specialty Health. He also held various roles at Oncology Therapeutics Network. Khullar holds an MBA from the University of San Francisco and a BA in history with a minor in computer science and engineering, political science, and law and society from the University of California, San Diego.

Jan 09, 2020

T2 Biosystems: John Sperzel, John McDonough

T2 Biosystems has appointed John Sperzel as president, CEO, and board member. He succeeds John McDonough, T2 Bio's outgoing president and CEO, who will serve as non-executive chairman of the board.

Sperzel has resigned as Chembio Diagnostics' president and CEO. Prior to Chembio, Sperzel served as president and CEO of ITC Medical, a privately-held point-of-care diagnostics company owned by Warburg-Pincus. Previously, Sperzel held executive and commercial leadership positions at Axis-Shield, Bayer Diagnostics, Instrumentation Laboratory, and Boehringer Mannheim.

Jan 09, 2020

Chembio Diagnostics: Gail Page

Chembio Diagnostics has appointed Gail Page, a company director, as its interim CEO and has initiated an executive search to identify a permanent CEO. John Sperzel has resigned as Chembio's president and CEO and replaced John McDonough as T2 Biosystems' president and CEO.

Page has served on Chembio's board of directors since 2017. She is a venture partner at Turret Capital Management and was previously president and CEO at Vermillion. Further, she served as chief operating officer of Luminex for three years and Roche Biomedical Laboratories, which is now Laboratory Corporation of America, for 12 years.

Jan 09, 2020

Todos: Gerald Commissiong, Daniel Hirsch

Todos Medical announced it appointed Gerald Commissiong as CEO and Daniel Hirsch as CFO. The company's former CEO, Herman Weiss, will stay on as the chairman of the board of directors. Commissiong is currently the president and CEO of Amarantus Bioscience Holdings and is the interim CEO of Breakthrough Diagnostics, the joint venture between Todos and Amarantus. He previously played football for the Calgary Stampeders of the Candian Football League and received his degree in management science and engineering from Stanford University.

Hirsch has spent 25 years of experience with public companies and a background in investor relations. Both executives will oversee Todos' relocation from Israel to the US. 

Jan 09, 2020

BioDirection: Jean-Luc Boulnois

BioDirection announced that Jean-Luc Boulnois has joined its board of directors.

Boulnois is the president and CEO of Quadrature, an advisory firm in the medical devices space. He has prevously developed early-stage companies, participated in an initial public offering, and led mergers, acquisitions, and financing rounds. Boulnois was involved with Microline Surgical for more than 18 years, first as an investor and later as CEO and executive chairman.

He has held senior-level positions at Dover Medical Ventures, Interactive Consulting, Sometec, Technomed International, and Arrow International. Boulnois serves on the boards of Fineheart, NidoSurgical, and Biomodex. 

Jan 08, 2020

Opko: Anthony Japour

Opko Health announced that its board appointed Anthony Japour as a new director, effective Jan. 6, until the company's 2020 annual stockholder meeting. Japour has been the medical director at Icon, a development outsourcer for the pharmaceutical, biotechnology, and medical devices industries, since 2016. He has also been the principal of consulting company Anthony Japour and Associates, Medical and Scientific Consulting since 2006. From 2012 to 2016, Japour was a physician at Elite Health Medical Group and South Florida Cardiology Associates. He is also a director for Cocrystal Pharma. 

Jan 08, 2020

Abbott: Brian Yoor, Robert Funck

Abbott announced Brian Yoor, the company's CFO and executive vice president, finance, will retire on Feb. 29, 2020. Yoor has been in his position since February 2017. Robert Funck will take over those roles on March 1. Funck has worked at Abbott since 1987 and served as the senior VP, finance. He has been Abbott's controller since 2013 and was VP, chief ethics and compliance officer from 2009 to 2013; VP, internal audit between 2007 and 2009; and VP and treasurer from 2005 to 2007.